Growth Metrics

Cytek Biosciences (CTKB) Preferred Stock Liabilities (2020 - 2021)

Cytek Biosciences filings provide 2 years of Preferred Stock Liabilities readings, the most recent being $194.3 million for Q2 2021.

  • On a quarterly basis, Preferred Stock Liabilities changed N/A to $194.3 million in Q2 2021 year-over-year; TTM through Jun 2021 was $194.3 million, a N/A change, with the full-year FY2020 number at $194.3 million, changed N/A from a year prior.
  • Preferred Stock Liabilities hit $194.3 million in Q2 2021 for Cytek Biosciences, roughly flat from $194.3 million in the prior quarter.
  • In the past five years, Preferred Stock Liabilities ranged from a high of $194.3 million in Q4 2020 to a low of $194.3 million in Q4 2020.